NDANASALSPRAYPriority Review
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Esketamine, the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N -methyl- D -aspartate (NMDA) receptor, an ionotropic glutamate receptor. The mechanism by which esketamine exerts its antidepressant effect is unknown. The major circulating metabolite of…
Indications (1)
Clinical Trials (1)
Reward Emotion Learning and Ketamine Study
Started Aug 2021
70 enrolled
DepressionMajor Depressive DisorderTreatment Resistant Depression
Loss of Exclusivity
LOE Date
Feb 18, 2040
169 months away
Patent Expiry
Feb 18, 2040
Exclusivity Expiry
Jan 17, 2028